UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
The report is the latest indictment of America’s broken healthcare system.
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
MinnPost45m
FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%
Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than ...
Zacks.com on MSN4h
FTC Report Reveals PBM Practices Impacting Competition and Drug Costs
The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
pharmaphorum7h
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Honolulu Star-Advertiser7h
FTC: Pharmacy managers inflated drug prices by $7.3 billion
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
ConsumerAffairs7h
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
Fox 919h
FTC says Optum, other prescription benefit managers inflate cancer drug prices 1,000%
Prescription benefit managers have been under growing scrutiny from state and federal regulators who have accused them of creating pharmacy deserts by steering consumers to their own pharmacies and ...
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of ...
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...